This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of GSK1363089 in Metastatic Gastric Cancer

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 29, 2008
Last updated: October 11, 2016
Last verified: October 2016
July 29, 2008
October 11, 2016
March 2007
November 2009   (Final data collection date for primary outcome measure)
  • Objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens [ Time Frame: 4 months (average) ]
  • Number of subjects with adverse events, and clinically significant changes in vital signs and laboratory values [ Time Frame: 4 months (average) ]
To determine the objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens , to evaluate the safety and tolerability of GSK1363089 on 2 different dosing regimens
Complete list of historical versions of study NCT00725712 on Archive Site
  • Median progression free survival (PFS) of GSK1363089 [ Time Frame: 4 months (average) ]
  • Duration of Stable Disease of GSK1363089 [ Time Frame: 4 months (average) ]
  • Peak and trough concentrations of GSK1363089 in plasma samples [ Time Frame: first 8 weeks of study treatment ]
  • Disease stabilization rate of GSK 1363089 [ Time Frame: 4 months (average) ]
  • Median overall survival of GSK1363089 [ Time Frame: 6 months (average) ]
  • Plasma concentrations of soluble MET, HGF, soluble VEGFR2 and VEGFA [ Time Frame: first 8 weeks of study treatment ]
To evaluate progression free survival (PFS), duration of response, and overall survival, to characterize pharmacokinetic (PK) and pharmacodynamic parameters of GSK1363089
Not Provided
Not Provided
Study of GSK1363089 in Metastatic Gastric Cancer
A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Neoplasms, Gastrointestinal Tract
Drug: GSK1363089 (formerly XL880)
c-MET tyrosine kinase inhibitor
Other Name: foretinib
  • Experimental: 5-days on/9-days off
    Dosing for first 5 days in every 14-day period.
    Intervention: Drug: GSK1363089 (formerly XL880)
  • Experimental: daily dosing
    dosed every day
    Intervention: Drug: GSK1363089 (formerly XL880)

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2009
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • histologically confirmed diagnosis of advanced or metastatic gastric carcinoma, or adenocarcinoma of the gastroesophageal junction or of the distal esophagus. Subjects with tumors of the gastroesophageal junction or of the distal esophagus may be eligible provided that the tumor is not of squamous or sarcomatous histology
  • Measurable disease
  • The subject consents to provide paired tumor biopsies, directly prior to commencing study treatment and then between Days 5 and 8.
  • The subject has an ECOG performance status ≤2.
  • The subject is able to ingest the GSK1363089 capsules.
  • In the adrenocorticotropic hormone (ACTH) stimulation test, the subject has a serum cortisol level ≥20 μg/dL (552 nmol/L) 30-90 minutes after injection of ACTH.
  • The subject has liver, kidney and marrow function.
  • The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
  • Sexually active subjects (male and female) must use a medically-accepted method of contraception during the course of the study.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screening.
  • The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer or a malignancy diagnosed ≥5 years ago, and has no evidence of disease for 5 years prior to the screening for this study).
  • QTc < 470 msec.

Exclusion Criteria:

  • The subject has received more than two lines of prior cytotoxic chemotherapy for locally advanced or metastatic disease. For the purpose of this protocol, neoadjuvant therapy would not be considered to be prior cytotoxic chemotherapy. In addition, potential subjects who have received prior treatment with c-MET signaling inhibitor are excluded.
  • The subject has received an investigational drug within 14 days of the first dose of study drug.
  • The subject has received chemotherapy, immunotherapy, or radiation therapy (to

    ≥25% of his or her bone marrow) within 14 days or has received nitrosoureas or mitomycin C within 6 weeks prior to the scheduled first dose of GSK1363089.

  • The subject has AEs due to investigational drugs or other medications administered more than 21 days prior to enrollment that have not recovered to Grade ≤1 using NCI CTCAE v3.0, with the exception of alopecia greater than grade 1.
  • The subject has known brain metastases.
  • The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • The subject is pregnant or breastfeeding.
  • The subject is known to be positive for the human immunodeficiency virus (HIV).
  • The subject has a previously identified allergy or hypersensitivity to components of the GSK1363089 formulation.
  • The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Patient-level data for this study will be made available through following the timelines and process described on this site.
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP